OS Therapies Inc (OSTX): Entry into a Material Definitive Agreement
OS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ea029686801ex10-1.htm SECURITIES PURCHASE AGREEMENT, DATED AS OF JUNE 30, 2026, AMONG OS THERAPIES INCORPORATED, OS ANIMAL HEALTH INC., OS THERAPIES UK LTD AND LEONITE FUND I, LP Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “ Agreem
How this was made
The 30-second read
Why it matters
The transaction introduces new capital and financing structure (secured convert + equity/warrants), which can affect valuation via dilution expectations, conversion optionality, and near-term liquidity perceptions.
Market read
New disclosed financing terms (up to $10M principal, 7.5% OID, 275,000 shares, and a 1.75M-share warrant) create a fresh dilution/convertible overhang narrative for OSTX.
What to watch
OID (7.5%) and the warrant/share issuance imply embedded economics beyond headline principal; traders should model effective dilution and conversion/warrant strike terms (not included in the excerpt).
Background
The 8-K reports entry into a material definitive securities purchase agreement dated June 30, 2026, with Leonite Fund I, LP for a senior secured convertible promissory note financing.
Ticker impact
OS Therapies entered a securities purchase agreement for up to $10M senior secured convertible notes plus 275,000 shares and a 1.75M-share warrant.
Likely near-term volatility driven by dilution/convertible overhang, partially offset by cash infusion expectations.
The filing is a primary-source capital raise disclosure (8-K/Ex-10.1) with defined consideration (note principal, OID, shares, warrant). The exact tranche timing/total funding is not fully shown in the excerpt, limiting precision on dilution impact.
Market effects
Adds another small-cap biotech/animal-health financing example using secured convertibles with warrants, reinforcing ongoing risk appetite constraints for pre-commercial issuers.
Primarily US micro/small-cap sentiment; limited direct regional spillover beyond the issuer’s investor base.
Low; deal is company-specific and not tied to a global macro or cross-border regulatory event in the provided text.
Counterpoint
Because the note is “senior secured,” downside risk may be less than typical unsecured converts, potentially reducing tail risk versus other dilutive financings.
Key entities
- issuerOS Therapies Incorporated
Company entering the securities purchase agreement; subject of the 8-K.
- investorLeonite Fund I, LP
Purchaser of the senior secured convertible promissory note and related securities.
- subsidiaryOS Animal Health Inc.
Included as a party to the agreement.
- subsidiaryOS Therapies UK LTD
Included as a party; referenced in the “Assignment of Assets” context.
